Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of May 2023. The report details the status of the Company's Annual General Meeting of Shareholders convened on May 4, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The primary event noted is the adjournment of the Annual General Meeting due to a lack of quorum.
Guidance, Outlook, and Management Commentary
Management has announced that the Annual General Meeting, originally scheduled for May 4, 2023, was adjourned for one week. The meeting will be reconvened on Thursday, May 11, 2023, at 3:00 p.m. (Israel time) at the Company's executive offices in Rehovot, Israel. No specific business outlook, guidance, or risk factors are detailed in this specific notice.
Key Facts for Investor Verification
- The Annual General Meeting was adjourned on May 4, 2023, due to a lack of quorum.
- The reconvened meeting is scheduled for May 11, 2023, at 3:00 p.m. Israel time.
- This filing does not contain financial results; investors should refer to the Company's Form 20-F or other financial reports for performance data.